Catalyst Event
SK Biopharmaceuticals Co Ltd (326030) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
4/29/2026, 12:00:00 AM
An executive vice president is scheduled to announce a long-term revenue target for Cenobamate (Xcopri), aiming for $1 billion in U.S. sales by 2029 at the Bio Korea 2026 event on April 29, 2026; high importance is estimated as the $1B target is a critical valuation milestone for blockbuster status, scheduled.
Korean Translation
2026년 4월 29일 바이오 코리아 2026 행사에서 부사장이 세노바메이트(엑스코프리)의 2029년 미국 매출 목표 10억 달러 달성 계획을 발표할 예정이며, 이는 기업 가치에 중대한 영향을 미치는 요소로 높은 중요도로 예상됨.
Related Recent Events
AprilBio Co Ltd (397030) · Other
Final data from the Phase 1b clinical trial of APB-A1 for thyroid eye disease (TED) is scheduled to be presented at the ENDO conference on June 13, 2026. High importance is estimated due to the typical >10% price impact of clinical data, scheduled.
6/13/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Earnings Release
The company's quarterly earnings report is scheduled for May 18, 2026; a 5-10% price impact is estimated based on historical volatility, scheduled.
5/18/2026, 12:00:00 AM
Yuhan Corp (000100) · Earnings Release
Yuhan Corp. announced Q1 2026 earnings. Consolidated revenue was KRW 526.8B (+7.2% YoY) and operating profit was KRW 8.8B (+37.3% YoY). Operating profit missed market expectations due to the delayed recognition of a milestone payment for Lazertinib. Due to the earnings miss, a ~5% price impact is expected.
4/30/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Earnings Release
Announced Q1 2026 results: Revenue KRW 392.9B (+0.5% YoY), Operating Profit KRW 53.6B (-9.1% YoY), Net Profit KRW 51.1B (+14.4% YoY). The operating profit decline was attributed to a one-off base effect from prior year's clinical trial material supply.
4/30/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
Announced a strategic investment in US biotech 'General Proximity' to secure next-generation 'Induced Proximity' drug development technology, on April 30, 2026.
4/30/2026, 12:00:00 AM
Chong Kun Dang Pharm Co (185750) · Earnings Release
Announced Q1 2026 earnings with revenue of KRW 447.7 billion (+12.2% YoY) and operating profit of KRW 17.6 billion (+36.9% YoY), beating market expectations.
4/29/2026, 12:00:00 AM